USF researchers have identified five novel antimicrobial compounds applicable against several drug targets such as ESKAPE pathogens, Leishmania donovani, Mycobacterium tuberculosis (TB), Clostridium difficile, Naegleria fowleri, and cancer. These five compounds were isolated via a fungal metabolite screening program. Each compound exhibited specific bioactivity towards their target using strict activity cut-offs. For example, TB compounds were only included if they showed selective inhibition ≥ 85%, and Naegleria fowleri compounds were only included if they showed >33% inhibition. These novel inhibitory compounds include Phomopsichromin and Citreohybriddione. The specificity of these antimicrobial compounds and their derivatives are essential in future drug discovery efforts.
Competitive Advantages:
The Selectivity of the Five Newly Identified Active Extracts
Desired Partnerships: